Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
J-Pharma CoTSE:520A -2.36%9 Net Current Asset Value is 円131.04 as of Dec. 2025. GuruFocus rates TSE:520A with a GF Score™ of 9/100. Among 942 Biotechnology companies, J-Pharma Co ranks better than 76.43% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
J-Pharma Co's net current asset value per share for the quarter that ended in Dec. 2025 was 円131.04.
The historical rank and industry rank for J-Pharma Co's Net Current Asset Value or its related term are showing as below:
TSE:520A'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0 Med: 0 Max: 2.27
Current: 2.21
During the past 2 years, the highest Price-to-Net-Current-Asset-Value Ratio of J-Pharma Co was 2.27. The lowest was 0.00. And the median was 0.00.
TSE:520A's Price-to-Net-Current-Asset-Value is ranked better than 76.43% of 942
companies
in the Biotechnology industry
Industry Median: 4.89
vs TSE:520A: 2.21
J-Pharma Co (TSE:520A) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
J-Pharma Co Net Current Asset Value Related Terms
J-Pharma Co Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for J-Pharma Co's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
J-Pharma Co Net Current Asset Value Chart
J-Pharma Co Annual Data
Trend
Mar24
Mar25
Net Current Asset Value
52.30
132.37
J-Pharma Co Quarterly Data
Mar24
Mar25
Dec25
Net Current Asset Value
52.30
132.37
131.04
TSE:520A vs VRTX, REGN, ALNY: Net Current Asset Value Comparison
For the Biotechnology subindustry, J-Pharma Co's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
J-Pharma Co Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, J-Pharma Co's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where J-Pharma Co's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of 円131.04 mean?
J-Pharma Co (TSE:520A) has a Net Current Asset Value of 円131.04 as of Dec. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on J-Pharma Co and its competitors. According to the industry distribution chart, J-Pharma Co ranks #222 out of 942 companies in the Biotechnology industry, placing it in the top 23.6%.
Is J-Pharma Co's Net Current Asset Value too high?
J-Pharma Co's current Net Current Asset Value is 円131.04. Based on the distribution chart, J-Pharma Co ranks #222 out of 942 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, J-Pharma Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does J-Pharma Co's Net Current Asset Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, J-Pharma Co ranks #222 out of 942 companies for Net Current Asset Value. This places J-Pharma Co in the top 24% of its industry — outperforming the majority of peers. The industry median Net Current Asset Value is 4.89. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.89, based on 942 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on J-Pharma Co and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. J-Pharma Co's current Net Current Asset Value is 円131.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is J-Pharma Co stock overvalued right now?
J-Pharma Co (TSE:520A) has a current Net Current Asset Value of 円131.04. The current Net Current Asset Value is 円131.04. J-Pharma Co's overall GF Score™ is 9/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For J-Pharma Co (TSE:520A), the current Net Current Asset Value is 円131.04 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
J-Pharma Co Ltd is engaged in the Drug discovery and development targeting SLC transporters. It is focused on a single segment of the drug discovery business, focusing on R&D and clinical development. The company's two compounds in clinical development are Nanbran Latte (JPH203) and JPH034.
9GF Score
Get the complete analysis for TSE:520A
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:520A has been successfully added to your 
